Vertex announces expansion of reimbursement agreement with NHS England to include Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with Kalydeco (ivacaftor)

Vertex Pharmaceuticals

30 June 2020 - Cystic fibrosis patients in England will be among the first in Europe to benefit from access to Kaftrio, if the medicine is approved by the European Commission.

Vertex Pharmaceuticals today announced that it has expanded its reimbursement agreement with NHS England for Vertex’s cystic fibrosis medicines to include Kaftrio (ivacaftor/tezacaftor/elexacaftor), in a combination regimen with Kalydeco (ivacaftor) 150 mg, ahead of the medicine’s anticipated approval by the European Commission.

The new expanded agreement includes reimbursed access to Vertex’s currently licensed medicines — Kalydeko (ivacaftor), Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor), as well as the triple combination therapy if approved — and any future additional licensed indications for all of these medicines.

Read Vertex Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

England , Medicine , Market access